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OBJECTIVES The aim of this study was to assess the predictive potency of impaired endothelium-
dependent flow-mediated vasodilation (FMD) in patients with chronic heart failure (CHF).
BACKGROUND Chronic heart failure is associated with reduced FMD; the prognostic impact of this
observation is unknown.
METHODS Seventy-five ambulatory CHF patients (United Network of Organ Sharing [UNOS] status 2)
with a left ventricular ejection fraction (LVEF) 30%, despite optimized medical therapy
(angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker, 100%; beta-
blocker, 81%), were evaluated. Using high-resolution ultrasound, FMD of the brachial artery
was assessed in addition to other neurohormonal, clinical, and hemodynamic variables. Age,
gender, New York Heart Association (NYHA) functional class, LVEF, hemodynamic
variables, B-type natriuretic peptide (BNP) levels, medical therapy, cardiovascular risk factors,
and FMD were analyzed for prediction of the combined end point conversion to UNOS
status 1 or death in a multivariate Cox model.
RESULTS Up to three years, 21 patients (28%) converted to UNOS status 1, and 6 patients (8%) died.
Univariate risk factors for the combined end point were log BNP (p  0.0032), FMD (p 
0.0033), NYHA functional class (p  0.0132), beta-blocker therapy (p  0.0367), and mean
blood pressure (p  0.0406). In the multivariate analysis, only FMD (p  0.0007), log BNP
(p  0.0032), and mean blood pressure (p  0.0475) were independently related to the
combined end point. In the Kaplan-Meier plot, significantly more patients with FMD6.8%
(median) reached the combined end point, as compared with patients with FMD 6.8%
(p  0.004).
CONCLUSIONS In CHF, impaired FMD is a strong, independent predictor of conversion to UNOS status 1
or death. (J Am Coll Cardiol 2005;46:1011–8) © 2005 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.04.060Cardiology Foundation
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ohe vasodilatory, anti-inflammatory, and antithrombotic
roperties of the endothelium are markedly diminished by
arious injuries, including hypertension, hypercholesterol-
mia, smoking, and diabetes. This endothelial dysfunction
See page 1027
epresents a key step in the development of atherosclerosis and
s also involved in plaque progression. Several studies indicate
hat endothelial dysfunction, assessed as impaired
ndothelium-dependent flow-mediated vasodilation (FMD),
redicts an increased rate of adverse cardiovascular events,
ncluding acute coronary syndromes, ischemic stroke, critical
imb ischemia, coronary, carotid, and peripheral revasculariza-
ion procedures, and cardiovascular deaths (1–8).
Traditional cardiovascular risk factors like hypertension,
ypercholesterolemia, and obesity are associated with an
ncreased risk of developing chronic heart failure (CHF)
From the Department of Cardiology, Medical University of Vienna, Vienna,
ustria.p
Manuscript received November 24, 2004; revised manuscript received April 4,
005, accepted April 13, 2005.nd mortality in the general population. In patients with
HF, these risk factors are also related to outcome, but in
he opposite direction, high systemic blood pressure, hyper-
holesterolemia, and obesity have been shown to indicate a
etter survival. Various mechanisms may contribute to this
henomenon (9).
Independent of the traditional cardiovascular risk factors,
HF itself causes endothelial dysfunction of both large
onduit arteries and small resistance arteries (10). The
pecific mechanisms of impaired FMD in CHF include
ong-term decreased peripheral blood flow, cytokine activa-
ion, increased angiotensin-converting enzyme (ACE) ac-
ivity, increased oxidative stress, and increased endothelin
roduction (11,12). Long-term decreased peripheral blood
ow, cytokine activation, and increased ACE activity are
nvolved in the reduced synthesis and release of nitric oxide;
he increased production of oxygen free radicals contributes
o the inactivation of nitric oxide; and the increased endo-
helin production counteracts short-term vasodilation via
itric oxide by enhancing basal vascular tone (10,13). Each
f these factors has an important prognostic impact in
atients with CHF (14–18).
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FMD Predicts Outcome in CHF September 20, 2005:1011–8Endothelial dysfunction may enhance the progression of
HF via peripheral and central effects. Increased arterial
tiffness and reduced compliance increase ventricular after-
oad and left ventricular end-diastolic stress and enhance
ilation and failure (19,20). Central effects of endothelial
ysfunction include impaired function of the large epicardial
oronary arteries, as well as the coronary microcirculation,
hich may cause or contribute to myocardial ischemia (10).
We hypothesized that in CHF patients with severe left
entricular systolic dysfunction despite optimized medical
herapy, FMD differs between event-free survivors and
atients reaching the combined end point conversion to
nited Network of Organ Sharing (UNOS) status 1 or
eath and that FMD is a predictor of these end points.
ETHODS
tudy protocol. The recruitment of 75 ambulatory CHF
atients (UNOS status 2—patients without inotropic or
echanical circulatory support and without mechanical
entilation [21]) was planned. Inclusion criteria were a left
entricular ejection fraction (LVEF) 30% assessed by
adionuclide ventriculography within four weeks before
tudy entry and optimized medical therapy. Patients with an
cute myocardial infarction or coronary revascularization
rocedure within the last three months and patients with a
evere valvular stenosis or severe primary regurgitation of
he aortic or tricuspid valve were excluded from the study.
In eligible patients, a full clinical history was obtained and
xamination performed by a CHF specialist. Baseline de-
ographic data, functional status, CHF medication, and
ardiovascular risk factors were documented, and a 12-lead
lectrocardiogram was reviewed. Moreover, blood sampling
as performed 2 h after routine morning medications, and
ltrasound measurements of the brachial artery were per-
ormed 8 h after routine morning medications (and after an
-h fast).
The study end points were conversion to UNOS status 1
e.g., chronic inotropic support or implantation of a ven-
ricular assist device [21]) or death. For patients who
onverted to UNOS status 1 and then died or underwent
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
BNP  B-type natriuretic peptide
CHF  chronic heart failure
DCM  dilated cardiomyopathy
FMD  (endothelium-dependent) flow-mediated
vasodilation
HTx  heart transplantation
ICM  ischemic cardiomyopathy
LVEF  left ventricular ejection fraction
NMD  nitroglycerin-mediated vasodilation
NYHA  New York Heart Association
ROC  receiver-operating characteristic
UNOS  United Network for Organ Sharingeart transplantation (HTx) within the observation period, anly the first event was considered in the analysis. The
NOS status 2 HTx was treated as a censored observation
these patients were counted as survivors and removed from
ollow-up “alive” at the time of HTx). The maximum
ollow-up time for a single patient was defined as three
ears; follow-up closure was scheduled 1.5 years after
ecruitment of the last patient. The study was approved by
n institutional review committee, and all patients gave
nformed consent.
ollow-up. All patients had routine visits at our Heart
ailure Center, as clinically indicated. In case of refractori-
ess to optimized medical treatment (ongoing New York
eart Association [NYHA] functional class IIIb/IV) and
ocumented forward and backward failure (cardiac index
2.5 l/min/m2, pulmonary capillary wedge pressure 20
m Hg) and in the absence of contraindications, patients
ere considered HTx candidates. Patients were supported
ith positive inotropic agents or left ventricular assist
evices when clinically indicated; the treating physicians
ere unaware of the FMD and B-type natriuretic peptide
BNP) levels.
At the follow-up closing date (April 30, 2003) or three
ears after inclusion into the study, the medical records of all
atients were reviewed, and the outcome was assessed by
elephone calls.
ealthy subjects and control subjects. Nineteen healthy
oung subjects and 14 age- and gender-matched subjects
ith several risk factors (for adequate comparison) but
ithout systolic left ventricular dysfunction (excluded by
chocardiography) or coronary artery disease (excluded by
ngiography) served as two control groups. The demo-
raphic and clinical characteristics of these two groups are
iven in Table 1.
aboratory tests. Venous blood samples were obtained
fter 30 min of supine rest from an indwelling catheter. Test
ubes were placed on ice and separated immediately. Plasma
amples were stored at70°C until analysis. The BNP level
as measured using a commercially available fluorescence
mmunoassay (Triage BNP Test by Biosite Diagnostics
nc., San Diego, California).
ssessment of FMD and nitroglycerin-mediated vasodi-
ation (NMD). Ultrasound measurements were performed
ccording to the guidelines for the ultrasound assessment of
MD of the brachial artery (22). Using high-resolution
ltrasound (Sonos 2500, Hewlett-Packard, Andover, Mas-
achusetts) with a 7.5-MHz linear array transducer, diam-
ter measurements of the right brachial artery were taken
fter supine rest for at least 10 min, after cuff deflation
ompleting suprasystolic compression (50 mm Hg above
ystolic pressure) of the right upper arm for 5 min and after
ublingual application of 0.8 mg nitroglycerin. A stereotac-
ical arm was used for optimal transducer positioning on the
rachial artery proximal of the bifurcation of the radial and
lnar arteries. The longitudinal image of the artery was
ecorded at baseline, continuously from 30 s before to 2 min
fter cuff deflation, and for 5 min after nitroglycerin admin-
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September 20, 2005:1011–8 FMD Predicts Outcome in CHFstration. Electrocardiographic gating was used during im-
ge acquisition to determine the diameter at the same time
n the cardiac cycle. The baseline diameter and maximum
MD and NMD diameters were measured from one
edia-adventitia interface to the other. Vasodilation was
hen calculated as the percent change in diameter over the
aseline value.
To verify that suprasystolic compression of the brachial
rtery produced an adequate increase in blood flow, flow
elocity was measured at rest and within 15 s after cuff
eflation. Despite using a stereotactical arm, the collapse of
he brachial artery and a shift in soft tissue by the compres-
ion of the upper arm (22) sometimes required an optimi-
ation of the transducer position, which could have delayed
he assessment of the hyperemic velocity after the optimal
ime point. Blood flow was calculated by multiplying the
elocity-time integral by the heart rate and the vessel
ross-sectional area (3.14  [D2/4], where D indicates
iameter). Reactive hyperemia was then calculated as the
ercent change in flow during hyperemia over the baseline
alue.
ample size and predefined observation period. Sample
ize calculation for log-rank tests (23) was estimated based
n the following assumptions: BNP, an excellent prognostic
arker in CHF, showed a hazard ratio of 12 in patients
ith high compared with low BNP values (60% vs. 5% end
oint rate [24]). Because these data were acquired in the pre
eta-blocker era, a 50% risk reduction by beta-blockers was
aken into account. Assuming that FMD could be a strong
ut less powerful predictor than BNP, sample size calcula-
ion was performed using an expected hazard ratio of 3.
rom previous data (18), we deducted a 34% biennial event
ate after adjustment for a 50% risk reduction due to
eta-blocker therapy, yielding a ratio of survivors to non-
urvivors of 2:1 over the study period. The maximum
ollow-up time for a single patient was defined as three
ears. Follow-up closure was scheduled 1.5 years after
ecruitment of the last patient to ensure a minimum
ollow-up time of 1.5 years. Thus, assuming a recruitment
able 1. Characteristics of the Study Groups
Normal Subjects
(n  19)
Contr
(n
ge, yrs 31  10*†‡ 5
ender, M/F (%) 16/3 (84/16) 11/
MI, kg/m2 22.6  2.3*†‡ 26.
holesterol, mg/dl 188  24 21
DL cholesterol, mg/dl 111  24* 14
DL cholesterol, mg/dl 54  12† 4
istory of hypertension, n (%) 0*†‡
mokers, n (%) 0*†‡
iabetes mellitus, n (%) 0*†‡
Normal subjects versus control: p  0.0001 (age), p  0.009 (BMI), p  0.03 (LDL
ellitus). †Normal subjects versus survivors: p  0.0001 (age), p  0.001 (BMI), p
0.003 (diabetes mellitus). ‡Normal subjects versus patients who converted to UNOS
 0.009 (smokers), p  0.005 (diabetes mellitus). §Control subjects versus patien
BMI  body mass index; HDL  high-density lipoprotein; LDL  low-densityeriod of one year, a mean follow-up time of two years, a cean end point-free survival time of 20 months in the high
vent rate group (24), a hazard ratio of 3, and a ratio of
urvivors to non-survivors of 2:1, a test with an alpha of 0.05
nd a power of 0.80 would require a total sample size of 72
atients. Including a safety margin for patients lost to
ollow-up, we aimed for the recruitment of 75 patients.
tatistical analyses. Continuous variables are expressed as
he mean  SD. Differences between groups were analyzed
sing one-factor analysis of variance followed by Tukey’s
tudentized range test (if indicated) for continuous variables,
nd pairwise comparisons were performed by means of the
isher exact test for categorical variables. Linear regression
nalysis was used to determine the relationship between
MD, BNP, and LVEF. A Cox proportional hazard
egression analysis was performed to identify independent
redictors of the combined end point. The model was built
y introducing variables simultaneously or stepwise; the p
alue for entering and staying in the model was set at 0.05.
ecause BNP was not normally distributed, log values were
sed for analysis. Receiver-operating characteristic (ROC)
nalysis was calculated to assess the utility of FMD to
istinguish between survivors and patients who reached the
ombined end point. The event-free survival between vari-
us patient groups was compared by Kaplan-Meier analysis.
ifferences were considered significant at p  0.05.
ESULTS
atients. Seventy-five ambulatory patients (UNOS status
) who had routine visits at our Heart Failure Center
etween January 1999 and December 2001 were entered
nto the study. Demographic and clinical data of all patients
re given in Table 2. The etiology of the disease was verified
y coronary angiography; patients without75% stenosis of
major epicardial coronary artery were classified as having
ilated cardiomyopathy (DCM).
linical outcome. After a mean observation period of 561
344 days, 27 patients reached the combined end point
onversion to UNOS status 1 or death. Of 21 patients who
bjects
4)
Survivors
(n  48)
UNOS-1/Death
(n  27) p Value
* 55  9† 57  7‡ 0.0001
/21) 43/5 (90/10) 24/3 (89/11)
.3* 26.1  3.8† 26.0  4.4‡ 0.001
9 206  50 186  57 NS
1*§ 118  35 112  34§ 0.02
8 41  13† 42  14 0.04
* 32 (67)† 18 (67)‡
* 17 (35)† 8 (30)‡
* 17 (35)† 9 (33)‡
sterol), p  0.001 (history of hypertension), p  0.002 (smokers), p  0.03 (diabetes
3 (HDL cholesterol), p  0.0001 (history of hypertension), p  0.003 (smokers), p
1 or died: p 0.0001 (age), p 0.004 (BMI), p 0.0001 (history of hypertension),
converted to UNOS status 1 or died: p  0.02 (LDL cholesterol).
rotein; UNOS  United Network of Organ Sharing.ol Su
 1
5  9
3 (79
8  3
9  4
4  3
1  1
8 (57)
6 (43)
3 (21)
chole
 0.0
statusonverted to UNOS status 1, 11 underwent urgent HTx, 8
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FMD Predicts Outcome in CHF September 20, 2005:1011–8ied (6 due to progressive pump failure, 2 due to other
easons such as a thromboembolic complication after im-
lantation of a left ventricular assist device and stroke), and
survived within the predefined observation period. Addi-
ionally, six patients died suddenly. Forty-eight patients
urvived event free until the end of the observation period
n 42) or until elective HTx (n 6). Differences between
vent-free survivors and patients who reached the combined
nd point are given in Table 2.
omparison of study groups. Differences between
ender-matched healthy subjects, control subjects, event-
ree survivors, and patients who reached the combined end
oint are given in Table 1.
able 2. Characteristics of Chronic Heart Failure Patients Accor
Survivors
(n  48)
ge, yrs 55  9
ender, M/F (%) 43/5 (90/10)
iagnosis, n (%)
CM 19 (40)
CM 29 (60)
VEF, % 21  5
NP, pg/ml 264  413
og BNP 2.13  0.52
YHA functional class, n (%)
I 9 (19)
II 12 (25)
III 24 (50)
IV 3 (6)
ean systemic blood pressure, mm Hg 85  13
eart rate, beats/min 68  12
hythm, n (%)
Sinus rhythm 36 (75)
Atrial fibrillation 7 (15)
Pacemaker 5 (10)
eurohormonal antagonists
CE inhibitor, n (%) 47 (98)
% of target dose 152  59
T II receptor blocker, n (%) 13 (27)
eta-blocker, n (%) 43 (90)
% of target dose 75  42
ldactone, n (%) 20 (43)
CD, n (%) 11 (23)
CE  angiotensin-converting enzyme; AT  angiotensin; BNP  B-type natriuret
CM  ischemic cardiomyopathy; LVEF  left ventricular ejection fraction; NYHA
able 3. Results of Ultrasound Measurements in the Brachial Ar
Normal Subjects
(n  19)
Control
(n 
aseline diameter, mm 4.5  0.8 4.8 
aseline flow, ml/min 169  102 144 
yperemia diameter, mm 5.2  1.0 5.3 
yperemia flow 408  202 410 
yperemia, % 291  215 302 
MD, % 15.9  4.1*†‡ 10.8 
MD diameter, mm 5.4  1.1 5.5 
MD, % 19.8  6.2‡ 13.9 
Normal subjects versus controls; p  0.07 (FMD). †Normal subjects versus survivor
ied; p  0.0001 (FMD); p  0.005 (NMD). §Controls versus patients who conver
o UNOS status 1 or died; p  0.001 (FMD).
FMD  flow-mediated vasodilation; NMD  nitroglycerin-mediated vasodilation; UNasodilation and blood flow response. The results of the
ltrasound measurements in the brachial artery are given in
able 3. The mean time to reach peak FMD was 69 10 s.
essel size and hyperemia were similar in the study groups;
hus, it can be assumed that the stimulus for FMD was
imilar. However, FMD values were significantly impaired
n CHF survivors (11.2  7.4%, p  0.02) and in patients
ho reached the combined end point (5.4  5.1%, p 
.0001), and they tended to be impaired in control subjects
10.8  3.4%, p  0.07) as compared with the healthy
ubjects (15.9 4.1%). Moreover, FMD values were similar
etween the control subjects and CHF survivors (10.8 
.4% vs. 11.2  7.4%, p  NS), but differed between
to Their Outcome
UNOS-1/Death
(n  27) p Value
All
(n  75)
57  7 NS 55  8
24/3 (89/11) NS 67/8 (89/11)
NS
16 (59) 35 (47)
11 (41) 40 (53)
20  6 NS 21  5
443  372 0.05 328  406
2.43  0.55 0.02 2.24  0.55
0.07
1 (4) 10 (13)
5 (19) 17 (23)
15 (56) 39 (52)
6 (22) 9 (12)
81  10 NS 83  12
74  13 0.02 70  13
NS
17 (63) 53 (71)
7 (26) 14 (19)
3 (11) 8 (10)
27 (100) NS 74 (99)
160  52 NS 155  56
4 (15) NS 17 (23)
18 (67) 0.01 61 (81)
63  26 NS 71  38
8 (30) NS 28 (37)
2 (7) NS 13 (17)
ide; DCM  dilated cardiomyopathy; ICD  implantable cardioverter-defibrillator;
ew York Heart Association; UNOS  United Network of Organ Sharing.
cts Survivors
(n  48)
UNOS-1/Death
(n  27) p Value
4.9  0.7 4.9  0.8 NS
142  79 139  54 NS
5.4  0.7 5.2  0.8 NS
410  333 484  347 NS
272  138 339  185 NS
11.2  7.4† 5.4  5.1‡§ 0.0001
5.7  0.6 5.5  0.8 NS
15.4  8.3 12.7  5.1‡ 0.008
0.02 (FMD). ‡Normal subjects versus patients who converted to UNOS status 1 or
UNOS status 1 or died; p  0.04 (FMD). Survivors versus patients who converteddingtery
Subje
14)
0.8
60
0.9
110
114
3.4*§
0.9
4.7
s; p 
ted toOS  United Network of Organ Sharing.
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September 20, 2005:1011–8 FMD Predicts Outcome in CHFontrol subjects and CHF patients who reached the com-
ined end point (10.8 3.4% vs. 5.4 5.1%, p 0.04). As
he main result of this study, FMD values were significantly
mpaired in CHF patients who reached the combined end
oint as compared with CHF survivors (5.4 5.1% vs. 11.2
.4%, p  0.001). None of the healthy subjects had FMD
elow the median FMD (6.8%) of the CHF patients (Fig. 1).
By comparing the endothelium-independent vasodilator
apacity of the brachial artery, NMD values were similar
etween the control subjects (13.9  4.7%), CHF survivors
15.4  8.3%), and CHF patients who reached the com-
ined end point (12.7  5.1%). The NMD values of the
ealthy subjects (19.8  6.2%) were slightly higher com-
ared with the NMD values of the three groups, but a
ignificant difference could only be detected between
ealthy subjects and CHF patients who reached the com-
ined end point (19.8  6.2% vs. 12.7  5.1%, p  0.005).
n accordance, Schächinger et al. (1) demonstrated that
mpaired NMD of coronary arteries is also associated with a
ignificantly higher incidence of cardiovascular events.
ubanalysis of patients with DCM and patients with
schemic cardiomyopathy (ICM). As listed in Table 2, 16
46%) of 35 patients with DCM and 11 (28%) of 40 patients
ith ICM reached the combined end point. In accordance
ith the whole study population, FMD also differed in the
ubgroup of DCM patients (11.1  7.7% vs. 5.6  4.5%,
 0.02) and in the subgroup of ICM patients (11.3 
.4% vs. 5.1 6.1%, p 0.02) between event-free survivors
nd patients who reached the combined end point (Fig. 1).
elationship between FMD and NYHA functional
lass. Flow-mediated dilation was significantly higher in
atients in NYHA functional class I compared with class IV
Fig. 2). Interestingly, no correlation was found between
MD and BNP levels or between FMD and LVEF (30%
n all patients) in a linear regression analysis.
nivariate and multivariate predictors of the combined
nd point. Univariate indicators for the combined end
oint were log BNP (p  0.0032), FMD (p  0.0033),
igure 1. The mean endothelium-dependent flow-mediated vasodilation
FMD) of event-free survivors (open bars) compared with patients who
onverted to United Network for Organ Sharing status 1 or died (solid
ars) in all chronic heart failure patients and in the subgroups of patientsf
ith dilated cardiomyopathy (DCMP) and ischemic cardiomyopathy
ICMP).YHA functional class (p  0.0132), beta-blocker therapy
0.0367), and mean blood pressure (p  0.0406) (Table 4).
ntroducing FMD and three univariate clinical predictors—
YHA functional class, beta-blocker therapy, and mean
lood pressure—simultaneously in a multivariate model,
MD (chi-square  5.1175, p  0.0237) and mean blood
ressure (chi-square  4.0838, p  0.0433) were the only
ndependent predictors of the combined end point. When
lso introducing log BNP in this model, only log BNP
chi-square  11.0171, p  0.0009) and FMD (chi-
quare  6.0157, p  0.0142) were independent predic-
ors. In accordance, in the multivariate stepwise regres-
ion analysis, only FMD (chi-square  11.5363, p 
.0007), log BNP (chi-square  8.7129, p  0.0032),
nd mean blood pressure (chi-square  3.9289, p 
.0475) were independently related to the combined end
oint (Table 4).
In order to identify a potential cutoff, another analysis
as performed using the categorical variable FMD (below
nd above the median of 6.8%). Again, FMD was a strong
nivariate predictor (chi-square  8.1911, p  0.0042) and
ne of two independent predictors of the combined end
oint in the multivariate stepwise model (log BNP: chi-
quare 8.7129, p 0.0032; FMD: chi-square 16.2788,
 0.0001).
nivariate predictors of sudden death, pump failure
eath, and conversion to UNOS status 1. Analyzing
vent-free survivors and patients who died suddenly, uni-
ariate predictors of sudden death were log BNP (p  0.02)
nd beta-blocker therapy (p  0.02). By analyzing survivors
nd patients who died from pump failure, univariate pre-
ictors of pump failure death were log BNP (p  0.006),
MD (p  0.01), and NYHA functional class (p  0.01).
y analyzing survivors and patients who converted to
NOS status 1, univariate predictors of conversion to
NOS status 1 were FMD (p  0.001), NYHA functional
lass (p  0.002), log BNP (p  0.02), and mean blood
ressure (p  0.03).
OC analysis. The area under the ROC curve using FMD
igure 2. The mean endothelium-dependent flow-mediated vasodilation
FMD) of 10 patients in New York Heart Association (NYHA) functional
lass I, 17 in class II, 39 in class III, and 9 in class IV .or discriminating patients who reached the combined end
p
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FMD Predicts Outcome in CHF September 20, 2005:1011–8oint from survivors was 0.76 (Fig. 3). The mean FMD of
.8% in CHF patients had a sensitivity of 63% and a
pecificity of 67%.
aplan-Meier survival estimation. Using Kaplan-Meier
nalysis, event-free survival rates were significantly higher in
atients with FMD 6.8% (median) compared with pa-
ients with FMD 6.8% (p  0.004). Seven (19%) of 37
atients above, but 20 (53%) of 38 patients below this cutoff
alue converted to UNOS status 1 or died (Fig. 4).
ombining FMD and BNP to a prognostic factor.
hen stratifying patients according to the median of FMD
nd BNP levels and combining these stratifications to one
actor (group A: FMD6.8%, BNP208 pg/ml [n 17];
roup B: FMD 6.8%, BNP 208 pg/ml [n  21]; group
: FMD 6.8%, BNP 208 pg/ml [n  20]; group D:
Table 4. Univariate and Multivariate Predictor
Univariate
Chi-Square
Log BNP 8.7129
FMD 8.6369
NYHA functional class 6.1407
Beta-blocker 4.3642
Mean BP 4.1943
Cholesterol 3.5792
Age 2.3351
Diagnosis 2.1113
LDL 1.0621
Smoking 0.8671
BMI 0.7944
LVEF 0.5852
ACE inhibitors 0.3688
Gender 0.0692
HDL 0.0013
Diabetes mellitus 0.0001
ACE  angiotensin-converting enzyme; BMI  body mass
FMD  flow-mediated vasodilation; HDL  high-densi
ventricular ejection fraction; NYHA  New York Heart As
igure 3. The receiver-operating characteristic curve illustrates the sensi-
ivity and specificity of endothelium-dependent flow-mediated vasodilation
FMD) in discriminating patients who reached the combined end point
rom survivors (FMD 6.8%; sensitivity 63%, specificity 67%). The area
nder the curve (AUC) was 0.76.
d
eMD 6.8%, BNP 208 pg/ml [n  17]), this factor was
he only independent predictor of the combined end point
n the multivariate analysis (chi-square  24.9390,
 0.0001). No patient in group A, 7 patients in group B
33%), 7 patients in group C (35%), and 13 patients in
roup D (76%) reached the combined end point, resulting
n a highly significant difference between groups (except
etween groups B and C) in the Kaplan-Meier analysis
Fig. 5).
ISCUSSION
low-mediated dilation significantly differed between
vent-free survivors and patients who reached the combined
nd point conversion to UNOS status 1 or death in 75 CHF
atients with LVEF 30% despite optimized medical
herapy. Impaired FMD was a strong predictor of the
ombined end point in these patients, independent of BNP
dverse Outcome
sis
Multivariate Stepwise
Analysis
p Value Chi-Square p Value
0.0032 8.7129 0.0032
0.0033 11.5363 0.0007
0.0132
0.0367
0.0406 3.9289 0.0475
0.0585
0.1265
0.1462
0.3027
0.3518
0.3728
0.4443
0.5436
0.7924
0.9717
0.9935
; BNP  B-type natriuretic peptide; BP  blood pressure;
protein; LDL  low-density lipoprotein; LVEF  left
on.
igure 4. Kaplan-Meier analysis showing cumulative rates of event-free
urvival in 75 patients with chronic heart failure stratified into two groups
ccording to the median of endothelium-dependent flow-mediated vaso-s of A
Analy
indexilation (FMD). Patients with FMD 6.8% had a significantly better
vent-free survival compared with patients with FMD6.8% (p 0.004).
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September 20, 2005:1011–8 FMD Predicts Outcome in CHFevels and various other clinical factors previously associated
ith a poor prognosis.
ndothelial dysfunction as prognostic marker—previous
tudies. In accordance with our findings, various other
tudies have already proved the prognostic potency of
ndothelial function to predict future adverse events (1–8).
n some of these investigations, as well as in our study, the
ltrasound evaluation of the brachial artery was used for
ssessment of FMD (6–8). The study population in these
nalyses included patients with hypertension (3), various
ardiovascular risk factors (5), non-significant (2) or signif-
cant coronary artery disease (6), peripheral artery disease
7,8), a mixed patient population (1) or patients undergoing
ascular surgery (4), and the study end points were clinical
vents resulting from atherosclerotic complications. Our
atient population differs from those of previous studies
ecause it consists exclusively of patients with severe systolic
eft ventricular dysfunction. Despite various cardiovascular
isk factors, CHF patients are not at high risk of athero-
clerotic complications but are at high risk of sudden cardiac
eath or clinical deterioration and death due to progressive
ump failure (9). In the present study, we demonstrate that
ndothelial function predicts these CHF specific events,
eterioration to UNOS status 1, or death.
The predictive impact of endothelial function in CHF
atients is supported by several facts. First, the mechanisms
ontributing to impaired FMD in CHF, which include
ong-term decreased peripheral blood flow, cytokine activa-
ion, increased ACE activity, increased oxidative stress, and
ncreased endothelin production, are per se strong predictors
f adverse events in CHF (14–18). Second, impaired FMD
ay enhance the progression of CHF via an increase of
entricular afterload (19,20) and myocardial ischemia (10).
hird, impaired FMD is causatively involved in the devel-
pment of reduced functional capacity, an established prog-
ostic marker in CHF (25–27). Rather than the extent of
igure 5. Kaplan-Meier analysis showing cumulative rates of event-free surv
o their endothelium-dependent flow-mediated vasodilation (FMD) and B
g/ml; group B: FMD 6.8%, BNP 208 pg/ml; group C: FMD 6.8%entral hemodynamic disturbances and pulmonary abnor- Ualities like increased death space ventilation, impaired
keletal muscle function represents the major determinant of
xercise capacity (28). The histologic and biochemical
bnormalities of the skeletal muscle in CHF are probably
aused by reduced blood flow to the exercising muscle
10,28,29). Indeed, in CHF patients, the severity of impair-
ent of endothelium-dependent vasodilation correlates
ith exercise capacity and functional class (30). Our find-
ngs are consistent with these reports, as FMD decreases
ith increasing functional class.
NP and FMD—two strong independent prognostic
arkers. In several studies, BNP was demonstrated to be a
trong independent predictor of adverse outcome in CHF
24,26,27,31). Our data support these findings but also
how that, besides BNP, FMD is another strong indepen-
ent prognostic marker in CHF patients. Moreover, when
ombining FMD and BNP levels as one factor, this factor
as by far the strongest independent predictor of adverse
utcome in the multivariate analysis. Considering the al-
eady described association between FMD and functional
apacity, our data are in accordance with those of other
roups. They demonstrate that BNP and peak oxygen
onsumption, a marker of functional capacity, are two
trong independent predictors of outcome, and that the
ombination of both improves risk stratification in these
atients (26,27).
rognostic power of FMD according to underlying heart
isease. Endothelium-mediated vasodilation is similarly
mpaired in patients with DCM and ICM (32); perhaps
mpairment is slightly more pronounced in ICM patients
32). Possible slight differences concerning the responsible
echanisms of reduced FMD in DCM and ICM are under
iscussion (32,33). Nevertheless, our data demonstrate that
MD differs similarly in ICM and DCM patients between
vent-free survivors and patients who died or converted to
n 75 patients with chronic heart failure stratified into four groups according
e natriuretic peptide (BNP) levels—group A: FMD 6.8%, BNP 208
P 208 pg/ml; and group D: FMD 6.8%, BNP 208 pg/ml.ival iNOS status 1.
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FMD Predicts Outcome in CHF September 20, 2005:1011–8tudy limitations. A limitation of the study is the use of
NOS status 1 as a negative end point, as patients in
NOS status 1 have not died. Nevertheless, the expected
urvival experience of these patients without HTx is much
loser to that of patients who have died than it is to patients
ho remain in UNOS status 2 (34). Indeed, 38% of our
atients who converted to UNOS status 1 died and 52%
nderwent urgent HTx within the observation period.
Another limitation is the small sample size and multiple
ariables entered into the multivariate model. Therefore, the
ndings might be influenced by the confounding effects of
easured or unmeasured risk factors.
onclusions. In CHF, impaired FMD is a strong predic-
or of adverse outcome, independent of BNP levels and
arious other clinical factors previously associated with a
oor prognosis. The predictive value of FMD may result
rom a summation of various factors that contribute to
ndothelial dysfunction and that have known prognostic
mportance. Moreover, the prognostic potency of FMD
ay also reflect its impact on the progression of the disease.
herefore, impaired FMD might be an important tool for
he assessment of patients with CHF.
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